Action Pharma A/S – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 40
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A702FF13AD6EN
Leaflet:

Download PDF Leaflet

Action Pharma A/S – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Action Pharma A/S - Product Pipeline Review - H2 2011” provides data on the Action Pharma A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Action Pharma A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from Action Pharma A/S and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Action Pharma A/S - Brief Action Pharma A/S overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Action Pharma A/S human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Action Pharma A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Action Pharma A/S’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Action Pharma A/S’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Action Pharma A/S in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Action Pharma A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Action Pharma A/S.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Action Pharma A/S and identify potential opportunities in those areas.
Action Pharma A/S Snapshot
Action Pharma A/S Overview
Key Information
Key Facts
Action Pharma A/S – Research and Development Overview
Key Therapeutic Areas
Action Pharma A/S – Pipeline Review
Pipeline Products by Stage of Development
Action Pharma A/S – Pipeline Products Glance
Action Pharma A/S Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Action Pharma A/S–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Action Pharma A/S – Drug Profiles
AP1030
  Product Description
  Mechanism of Action
  R&D Progress
AP214
  Product Description
  Mechanism of Action
  R&D Progress
AP405
  Product Description
  Mechanism of Action
  R&D Progress
Action Pharma A/S – Pipeline Analysis
Action Pharma A/S – Pipeline Products by Therapeutic Class
Action Pharma A/S - Pipeline Products By Target
Action Pharma A/S – Pipeline Products by Route of Administration
Action Pharma A/S – Pipeline Products by Molecule Type
Action Pharma A/S – Recent Pipeline Updates
Action Pharma A/S - Dormant Projects
Action Pharma A/S – Locations And Subsidiaries
Head Office
Recent Developments
Mar 29, 2010: Action Pharma Completes Dosing In Phase II Clinical Trial With AP214 To Prevent Acute Kidney Injury Associated With Cardiac Surgery
Sep 26, 2011: Action Pharma’s Phase IIb Clinical Trial With AP214 To Prevent Kidney Injury Associated With Major Cardiac Surgery Demonstrates Positive Top-Line Results
Jun 25, 2008: Action Pharma Launches A Phase II Clinical Trial With AP 214 For The Treatment Of Organ Failure Associated With Major Cardiovascular Surgery
Oct 20, 2009: Action Pharma In New Phase II Clinical Trial
Jun 16, 2008: Action Pharma Presents Pre-Clinical Data For Treatment Of Type 2 Diabetes
Sep 13, 2010: Action Pharma Obtains Positive Results In A Phase Ii Clinical Trial With Ap214 To Prevent Acute Kidney Injury Associated With Cardiac Surgery
May 09, 2011: Action Pharma Completes Dosing In Phase IIb Clinical Trial With AP214 To Prevent Acute Kidney Injury Undergoing Cardiac Surgery
Nov 08, 2010: Action Pharma Initiates Phase IIb Clinical Trial In US And Denmark With AP214 To Prevent Kidney Injury
Aug 08, 2011: Final Patient Completes Last Visit In Action Pharma’s Phase IIb Clinical Trial Of Ap214
Mar 08, 2010: Action Pharma Reports Positive Results In A Proof Of Concept Phase IB Study In Obese Human Volunteers Treated With Small Molecule Oral Once-Daily AP1030 Targeted For Type II Diabetes Associated With Obesity
Financial Deals Landscape
Action Pharma A/S, Deals Summary
Action Pharma A/S, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Action Pharma Secures $6.1 Million In Series C Venture Financing
Action Pharma Secures $22 Million In Series D Financing Round
Action Pharma Secures $7.6 Million In Venture Financing
Action Pharma Secures $3.11 Million In Second Round Of Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Action Pharma A/S – Pipeline by Therapy Area and Indication, H2 2011
Action Pharma A/S – Pipeline by Stage of Development, H2 2011
Action Pharma A/S - Phase II, H2 2011
Action Pharma A/S - Phase I, H2 2011
Action Pharma A/S - Pipeline By Therapeutic Class, H2 2011
Action Pharma A/S - Pipeline By Target, H2 2011
Action Pharma A/S – Pipeline By Route of Administration, H2 2011
Action Pharma A/S – Pipeline By Molecule Type, H2 2011
Action Pharma A/S – Recent Pipeline Updates, H2 2011
Action Pharma A/S - Dormant Developmental Projects, 2010
Action Pharma A/S, Deals Summary
Action Pharma Secures $6.1 Million In Series C Venture Financing
Action Pharma Secures $22 Million In Series D Financing Round
Action Pharma Secures $7.6 Million In Venture Financing
Action Pharma Secures $3.11 Million In Second Round Of Financing

LIST OF FIGURES

Action Pharma A/S – Pipeline by Therapy Area and Indication, H2 2011
Action Pharma A/S – Pipeline by Stage of Development, H2 2011
Action Pharma A/S – Pipeline By Therapeutic Class, H2 2011
Action Pharma A/S – Pipeline By Route of Administration, H2 2011
Action Pharma A/S – Pipeline By Molecule Type, H2 2011

Ask Your Question

Action Pharma A/S – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: